Anemia drug by Takeda and Affymax is submitted for FDA OK

05/31/2011 | Forbes · Pharmaceutical Business Review Online

Affymax and Takeda Pharmaceutical are seeking FDA approval of peginesatide, a drug candidate for anemia in kidney dialysis patients. The once-monthly drug, formerly called Hematide, appears as safe and effective as epoetin alfa or epoetin beta in stabilizing hemoglobin level, according to results of two Phase III trials.

View Full Article in:

Forbes · Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ